

ANDA approval received by Glenmark Pharmaceuticals for Desonide Cream, 0.05%

31 July 2017 | News

Glenmark's current portfolio consists of 120 products authorized for distribution in the U.S. marketplace and 65 ANDA's pending approval with the U.S. FDA



Glenmark Pharmaceuticals Inc., USA has received an approval by the United States Food & Drug Administration (USFDA) for Desonide Cream, 0.05%.

It is the generic version of Desonide Cream, 0.05% of Perrigo New York Inc.

According to IMS Health sales data for the 12 month period ending May 2017, the Desonide Cream, 0.05% market1 achieved annual sales of approximately \$44.6 million.

Glenmark's current portfolio consists of 120 products authorized for distribution in the U.S. marketplace and 65 ANDA's pending approval with the U.S. FDA.